These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 3406665

  • 1. Rubella immunity and morbidity: effects of vaccination in Finland.
    Ukkonen P, von Bonsdorff CH.
    Scand J Infect Dis; 1988; 20(3):255-9. PubMed ID: 3406665
    [Abstract] [Full Text] [Related]

  • 2. Rubella immunity and morbidity: impact of different vaccination programs in Finland 1979-1992.
    Ukkonen P.
    Scand J Infect Dis; 1996; 28(1):31-5. PubMed ID: 9122630
    [Abstract] [Full Text] [Related]

  • 3. Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland.
    Peltola H, Karanko V, Kurki T, Hukkanen V, Virtanen M, Penttinen K, Nissinen M, Heinonen OP.
    Lancet; 1986 Jan 18; 1(8473):137-9. PubMed ID: 2867355
    [Abstract] [Full Text] [Related]

  • 4. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
    Peltola H, Heinonen OP, Valle M, Paunio M, Virtanen M, Karanko V, Cantell K.
    N Engl J Med; 1994 Nov 24; 331(21):1397-402. PubMed ID: 7969278
    [Abstract] [Full Text] [Related]

  • 5. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E, Tischer A.
    Gesundheitswesen; 1993 Jan 24; 55(1):38-9. PubMed ID: 8435543
    [Abstract] [Full Text] [Related]

  • 6. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland.
    Davidkin I, Peltola H, Leinikki P, Valle M.
    Vaccine; 2000 Jul 15; 18(27):3106-12. PubMed ID: 10856790
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Changes of the immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule.
    Christenson B, Böttiger M.
    Vaccine; 1991 May 15; 9(5):326-9. PubMed ID: 1872016
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE, Kumar ML, Whitwell JK, Staehle BO, Rome LP, Dinakar C, Hurni W, Nalin DR.
    Pediatr Infect Dis J; 1996 Aug 15; 15(8):687-92. PubMed ID: 8858673
    [Abstract] [Full Text] [Related]

  • 14. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A, Gerike E.
    Vaccine; 2000 Jan 31; 18(14):1382-92. PubMed ID: 10618536
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Rubella control in Papua New Guinea: age-specific immunity informs strategies for introduction of rubella vaccine.
    Riddell M, Senn N, Clements CJ, Hobday L, Cowie B, Kurubi J, Kevin A, Siba P, Reeder JC, Morgan C.
    Vaccine; 2012 Dec 14; 30(52):7506-12. PubMed ID: 23103194
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.